Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

Published:2023-01 Issue:1 Volume:24 Page:40-50
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Schmid Sabine,Cheng Sierra,Chotai Simren,Garcia Miguel,Zhan Luna,Hueniken Katrina,Balaratnam Karmugi,Khan Khaleeq,Patel Devalben,Grant Benjamin,Raptis Roula,Brown M. Catherine,Xu Wei,Moriarty Patrick,Shepherd Frances A.,Sacher Adrian G.,Leighl Natasha B.,Bradbury Penelope A.,Liu Geoffrey

Funder

Swiss Cancer Research Foundation

Takeda Canada Inc

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. ALK in lung cancer: past, present, and future;Shaw;J Clin Oncol,2013

2. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer;Remon;Cancer Treat Rev,2021

3. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer;Lung Cancer;2024-09

2. Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis;Lung Cancer Management;2024-03-13

3. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L);Therapeutic Advances in Medical Oncology;2024-01

4. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases;Pharmacological Research;2024-01

5. Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis;Exploration of Targeted Anti-tumor Therapy;2023-12-01